In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents.

In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Average weight reduction was 13.1% four months after placement, with no serious adverse events or early device removals.

Obesity among adolescents is a growing concern. According to the World Health Organization, worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled.1 These trends are particularly concerning as living with obesity in childhood or adolescence can lead to obesity-related complications in adulthood.2,3 Prior research has shown that while bariatric surgical procedures have become a more common treatment in adults living with obesity, patients, families, and providers are hesitant about the use of these invasive procedures in adolescents.4 In addition, earlier this year, the United States Preventive Services Task Force concluded that the evidence for the use of pharmacotherapy—including GLP-1 drugs—was inadequate in children and adolescents.5 This study affirms Allurion's belief that the Allurion Balloon represents a novel, non-invasive, safe, and effective treatment option for adolescents which can allow for earlier intervention in the treatment of obesity.

“Bariatric surgery and long-term pharmacotherapy, although effective in adults, raises concerns about invasiveness and potential risks when applied to adolescents,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe that the results of this study mark a significant milestone in the treatment of adolescent obesity, as the Allurion Balloon offers a non-invasive treatment option without several of the issues related to surgery and medications.”

Sources: 1. World Health Organization 2. Singh et al. Obes Rev. 2008;9(5):474-88. 3. Hassapidou et al. Obesity Facts. 2023;16(1):29-52. 4. Thenappan and Nadler. Current Gastroenterology Reports. 2019;21(6). 5. US Preventive Services Task Force. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226–232.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, including the VCS, to improve patient and clinical outcomes, including outcomes in adolescents, and the impact of gLP-1s on the Allurion Program. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

Global Media Cedric Damour PR Manager +33 7 84 21 02 20 cdamour@allurion.com Investor Mike Cavanaugh, Investor Relations ICR Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com

Allurion Technologies (NYSE:ALUR)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Allurion Technologies 차트를 더 보려면 여기를 클릭.
Allurion Technologies (NYSE:ALUR)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Allurion Technologies 차트를 더 보려면 여기를 클릭.